Agreements

Date: 2015-05-29

Type of information: Restructuring

Compound:

Company: Neostem (USA - NY) now Caladrius Biosciences (USA - NY)

Therapeutic area: Technology - Services - Cancer - Oncology - Cardiovascular diseases - Metabolic diseases

Type agreement: restructuring

Action mechanism:

Disease:

Details: * On May 29, 2015, NeoStem announced plans to change its corporate name to Caladrius Biosciences, effective June 8, 2015. PCT (Progenitor Cell Therapy , LLC), a wholly-owned subsidiary of NeoStem and an industry-recognized single source premier cell therapy service provider, will be renamed "PCT, a Caladrius company", also effective on June 8, with no change to its focus on process development, engineering and manufacturing for clients across the cell therapy industry. NeoStem's current therapeutic pipeline, for which new names for product candidates will be announced, includes:

• NBS20, the Company's lead product candidate, currently enrolling in the Intus Phase 3 trial for the treatment of metastatic melanoma, for which the first patient was randomized in April 2015;
• NBS10, for the treatment of damaged heart muscle after acute myocardial infarction, for which six and twelve month follow-up results have been announced; and
• NBS03D, which has been FDA-cleared for a Phase 2 study for the preservation of beta cell function in adolescents with type 1 diabetes. Caladrius will trade on the NASDAQ stock exchange under ticker symbol CLBS beginning on June 8, 2015.

Financial terms:

Latest news:

Is general: Yes